<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
SCHEDULE 14D-1
(AMENDMENT NO. 1)
TENDER OFFER STATEMENT PURSUANT TO
SECTION 14(d)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
UNIMED PHARMACEUTICALS, INC.
(NAME OF SUBJECT COMPANY)
SOLVAY S.A.
SOLVAY AMERICA, INC.
SOLVAY PHARMACEUTICALS, INC.
UTAH ACQUISITION CORPORATION
(BIDDERS)
COMMON STOCK, PAR VALUE $.25 PER SHARE
(TITLE OF CLASS OF SECURITIES)
904801 10 7
(CUSIP NUMBER OF CLASS OF SECURITIES)
JEFFREY D. LINTON
VICE PRESIDENT, LAW, GOVERNMENT AND PUBLIC AFFAIRS
SOLVAY PHARMACEUTICALS, INC.
901 SAWYER ROAD
MARIETTA, GEORGIA 30062
(770) 578-9000
WITH COPY TO:
EARL D. WEINER
SULLIVAN & CROMWELL
125 BROAD STREET
NEW YORK, NEW YORK 10004
(212) 558-4000
(NAME, ADDRESS AND TELEPHONE NUMBERS OF PERSON AUTHORIZED
TO RECEIVE NOTICES AND COMMUNICATIONS ON BEHALF OF BIDDER)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
SCHEDULE 14D-1
CUSIP NO. 904801 10 7 PAGE 2 OF 8 PAGES
<TABLE>
<S> <C> <C>
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: SOLVAY S.A.
S.S. OR I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSON
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS AF, WC
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) [ ]
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Belgium
- ---------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ---------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES
CERTAIN SHARES [ ]
- ---------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7) 0%
- ---------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON CO
- ---------------------------------------------------------------------------
</TABLE>
<PAGE> 3
SCHEDULE 14D-1
CUSIP NO. 904801 10 7 PAGE 3 OF 8 PAGES
<TABLE>
<S> <C> <C>
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: SOLVAY AMERICA, INC.
S.S. OR I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSON
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS AF, WC
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) [ ]
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
- ---------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ---------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES
CERTAIN SHARES [ ]
- ---------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7) 0%
- ---------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON CO
- ---------------------------------------------------------------------------
</TABLE>
<PAGE> 4
SCHEDULE 14D-1
CUSIP NO. 904801 10 7 PAGE 4 OF 8 PAGES
<TABLE>
<S> <C> <C>
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: SOLVAY PHARMACEUTICALS, INC.
S.S. OR I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSON
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS AF, WC
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) [ ]
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Georgia
- ---------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ---------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES
CERTAIN SHARES [ ]
- ---------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7) 0%
- ---------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON CO
- ---------------------------------------------------------------------------
</TABLE>
<PAGE> 5
SCHEDULE 14D-1
CUSIP NO. 904801 10 7 PAGE 5 OF 8 PAGES
<TABLE>
<S> <C> <C>
- ---------------------------------------------------------------------------
1 NAME OF REPORTING PERSON: UTAH ACQUISITION CORPORATION
S.S. OR I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSON
- ---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- ---------------------------------------------------------------------------
3 SEC USE ONLY
- ---------------------------------------------------------------------------
4 SOURCE OF FUNDS AF
- ---------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(e) or 2(f) [ ]
- ---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
- ---------------------------------------------------------------------------
7 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ---------------------------------------------------------------------------
8 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (7) EXCLUDES
CERTAIN SHARES [ ]
- ---------------------------------------------------------------------------
9 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (7) 0%
- ---------------------------------------------------------------------------
10 TYPE OF REPORTING PERSON CO
- ---------------------------------------------------------------------------
</TABLE>
<PAGE> 6
This Amendment No. 1 amends the Tender Offer Statement on Schedule 14D-1
filed on June 17, 1999 (the "Schedule 14D-1") by Solvay S.A., a Belgian societe
anonyme ("Parent"), Solvay America, Inc., a Delaware corporation ("Solvay
America") and a direct wholly owned subsidiary of Parent, Solvay
Pharmaceuticals, Inc., a Georgia corporation ("Purchaser") and a direct wholly
owned subsidiary of Solvay America, and Utah Acquisition Corporation, a Delaware
corporation ("Merger Sub") and a direct wholly owned subsidiary of Purchaser,
with respect to Merger Sub's offer to purchase all of the outstanding shares of
Common Stock, par value $.25 per share (the "Common Stock"), of Unimed
Pharmaceuticals, Inc., a Delaware corporation (the "Company"), including the
associated rights (the "Rights") issued pursuant to the Rights Agreement, dated
as of June 16, 1997, as amended as of June 11, 1999, between the Company and
Harris Trust and Savings Bank, as Rights Agent (the Common Stock and the Rights
together are referred to herein as the "Shares"), at $12.00 per Share, net to
the seller in cash (but subject to any applicable tax withholdings), on the
terms and subject to the conditions set forth in the Offer to Purchase, dated
June 17, 1999 (the "Offer to Purchase") and in the related Letter of Transmittal
(which collectively, together with any amendments or supplements thereto,
constitute the "Offer"), which were filed as Exhibits 1 and 2 to the Schedule
14D-1, respectively. Unless otherwise defined herein, all capitalized terms used
herein shall have the respective meanings given such terms in the Offer to
Purchase.
ITEM 10. ADDITIONAL INFORMATION.
Item 10(c) is amended and supplemented as follows:
The waiting period under the HSR Act applicable to the purchase of Shares
pursuant to the Offer expired at 11:59 p.m. on July 3, 1999. Expiration of such
waiting period was a condition to the Offer, and such condition has now been
satisfied.
Item 10(f) is amended and restated in its entirety as follows:
The information set forth in Section 13 of the Offer to Purchase, as
hereinafter amended, is incorporated herein by reference.
The text prior to the lettered clauses of the first paragraph under the
caption "13. Certain Conditions of the Offer" in the Offer to Purchase is
amended and restated in its entirety as follows:
"Notwithstanding any other provision of the Offer, Merger Sub shall not be
required to accept for payment or, subject to any applicable rules and
regulations of the SEC, including Rule 14e-1(c) under the Exchange Act
(relating to Merger Sub's obligation to pay for or return tendered Shares
promptly after termination or withdrawal of the Offer), pay for, or may
delay the acceptance for payment of, any tendered Shares, or may, in its
sole discretion, subject to the Merger Agreement, terminate or amend the
Offer as to any Shares not then paid for if, (i) prior to the expiration of
the Offer, (x) a number of Shares which, together with any Shares owned by
Purchaser, Merger Sub and the Purchaser Companies, constitutes more than
50% of the voting power (determined on a fully-diluted basis) of all the
securities of the Company entitled to vote generally in the election of
directors or in connection with a merger shall not have been validly
tendered and not withdrawn prior to the expiration of the Offer (the
"Minimum Condition") or (y) any waiting periods under the HSR Act
applicable to the purchase of Shares pursuant to the Offer shall not have
expired or been terminated, or any material approval, permit, authorization
or consent of any Governmental Entity shall not have been obtained on terms
satisfactory to the Purchaser in its reasonable discretion, or (ii) on or
after June 11, 1999, and at or before the Expiration Date, any of the
following events shall occur . . ."
Clause (c)(vii) of the first paragraph under the caption "13. Certain
Conditions of the Offer" in the Offer to Purchase is amended and restated in its
entirety as follows:
"(vii) that, in any event, in the reasonable judgment of Purchaser, is
reasonably likely to have a Material Adverse Effect or a material adverse
effect on the business, properties, results of operation or financial
condition of Purchaser (or any of its affiliates);"
6
<PAGE> 7
Clause (d) of the first paragraph under the caption "13. Certain Conditions
of the Offer" in the Offer to Purchase is amended and restated in its entirety
as follows:
"(d) any statute, rule, regulation, order or injunction shall be enacted,
promulgated, entered, enforced or deemed by a Governmental Entity or become
applicable to the Offer or the Merger or other subsequent business
combination, or any Action shall be instituted or pending brought by any
person or entity not on behalf of a Governmental Entity, or any other
action shall have been taken, proposed or threatened, by any court or other
Governmental Entity other than the application to the Offer or the Merger
or other subsequent business combination of waiting periods under the HSR
Act, that, in the reasonable judgment of Purchaser, is reasonably likely,
directly or indirectly, to result in any of the effects of, or have any of
the consequences sought to be obtained or achieved in, any Action referred
to in clauses (i) through (vii) of paragraph (c) above;"
The text following the lettered clauses of the first paragraph under the
caption "13. Certain Conditions of the Offer" in the Offer to Purchase is
amended and restated in its entirety as follows:
"which, in the reasonable judgment of Purchaser and Merger Sub, in any such
case, and regardless of the circumstances (including any action or inaction
by Purchaser or Merger Sub) giving rise to any such conditions, makes it
inadvisable to proceed with the Offer and/or with such acceptance for
payment of or payment for Shares."
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
Item 11 is hereby amended to add the following:
(15) Press release issued by Solvay Pharmaceuticals, Inc. on July 6, 1999.
7
<PAGE> 8
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: July 6, 1999
SOLVAY S.A.
By: /s/ JURGEN ERNST
------------------------------------
Name: Jurgen Ernst
Title: Director
Member of the Executive
Committee
By: /s/ RENE DEGREVE
------------------------------------
Name: Rene Degreve
Title: Director
Member of the Executive
Committee
SOLVAY AMERICA, INC.
By: /s/ PHILIP UHRHAN
------------------------------------
Name: Philip Uhrhan
Title: VP Finance
SOLVAY PHARMACEUTICALS, INC.
By: /s/ ROBERT A. SOLHEIM
------------------------------------
Name: Robert A. Solheim
Title: Vice President, Finance &
Administration
UTAH ACQUISITION CORPORATION
By: /s/ JEFFREY D. LINTON
------------------------------------
Name: Jeffrey D. Linton
Title: Vice President
8
<PAGE> 9
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
<S> <C>
(15) Press release issued by Solvay Pharmaceuticals, Inc. on July
6, 1999.
</TABLE>
<PAGE> 1
EXHIBIT 15
[SOLVAY PHARMACEUTICALS LETTERHEAD]
HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR SOLVAY GROUP'S
ACQUISITION OF UNIMED PHARMACEUTICALS, INC.
Solvay Pharmaceuticals, Inc. announced today that the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to
Solvay's tender offer for shares of Unimed Pharmaceuticals expired at
11:59 p.m. on July 3, 1999. Expiration of the waiting period was a condition to
the tender offer, and such condition has now been satisfied.
